Hers vs Found: Women's GLP-1 Weight Loss Programs Compared (2026)
An independent, side-by-side comparison of Hers and Found for GLP-1 weight loss programs — pricing, medications, protocols, and patient experience.

Quick Verdict
Best Price
Found
Starting at $149/mo vs $199/mo
Most Medications
Hers
2 medications vs 2
Best for Beginners
Hers
Hybrid, fast onboarding
Head-to-Head Comparison
Pricing Breakdown
Side-by-side pricing for every medication.
| Medication | Hers | Found | Savings |
|---|---|---|---|
| Semaglutide | $199/monthly | $149/monthly | Save $50/mo with Found |
| Tirzepatide | $399/monthly | $399/monthly | Similar pricing |
Pros and Cons
Hers
- Clean, women-focused branding and content on hormonal weight management, postpartum weight, and menopause
- Competitive pricing at $199/mo all-in, no hidden membership fees
- Compounded oral semaglutide available
- Fast process
- Backed by a publicly traded company (NYSE: HIMS)
- Free shipping included
- Async-only consultations
- GLP-1 program is identical to Hims
- No compounded tirzepatide option
- No lifestyle coaching, nutrition guidance, or behavioral support (unlike Calibrate, Found, or WeightWatchers Clinic)
- Compounded semaglutide availability subject to ongoing FDA regulatory action
- More expensive than Ro ($149) and Henry Meds ($149) for compounded semaglutide
Found
- Holistic approach — medication + coaching + community
- Board-certified obesity medicine specialists
- Competitive compounded semaglutide pricing
- Personalized weight-loss plans with behavior change focus
- Slower shipping than competitors (5-7 days)
- No lab testing included
- Coaching quality can vary
- Limited to weight-loss medications only
How They Compare
Our editorial assessment across key dimensions.
In-Depth Comparison
By sarah-chen · Last updated April 14, 2026
Hers vs Found: Women's GLP-1 Weight Loss Programs Compared
Hers (the women's brand from Hims & Hers) and Found both serve women seeking GLP-1 weight loss support. Hers is a women-branded consumer health platform offering GLP-1 alongside other health services. Found is a dedicated weight management platform with a broader medication menu and more individualized clinical approach. Here is how they compare.
Quick Verdict
| Hers | Found | |
|---|---|---|
| Monthly cost | ~$199/month | ~$99–199/month |
| Best for | Women wanting GLP-1 in a women's-focused brand experience | Women wanting medication flexibility + personalized coaching |
| Medication options | Primarily semaglutide | GLP-1 + metformin, naltrexone-bupropion, phentermine, spironolactone |
| Women-specific care | Yes — integrated with Hers platform | Moderate |
| PCOS support | Limited | Better — non-GLP-1 options matter for PCOS |
| Coaching | Basic | Personalized health coach |
| Tirzepatide | Limited | Limited |
The Women's Health Context
Hers positions itself specifically as a women's health platform, covering birth control, mental health, skincare, hair, and sexual health alongside weight management. The advantage: a single platform for multiple women's health needs; a brand voice that speaks specifically to women. The limitation: weight management is one service among many, not Hers' primary clinical focus.
Found serves both men and women but doesn't position itself as a women's brand. However, its broader medication menu — including spironolactone (commonly used for PCOS, hirsutism, and hormonal acne) — makes it more relevant to women with hormonal conditions like PCOS.
Medication Options: Found's Advantage for Women
| Medication | Hers | Found | Why It Matters for Women |
|---|---|---|---|
| Compounded semaglutide | Yes | Yes | Primary GLP-1 option |
| Metformin | No | Yes | Insulin resistance in PCOS |
| Naltrexone-bupropion | No | Yes | Emotional eating; compulsive food behaviors |
| Spironolactone | No | Yes | PCOS, hirsutism, hormonal acne alongside weight |
| Phentermine | No | Yes | Short-term appetite suppression option |
| Topiramate | No | Yes | Combination weight loss |
The PCOS case: Women with PCOS benefit from GLP-1 for insulin resistance — but many also benefit from metformin (insulin sensitizer) and/or spironolactone (androgen blocker for hirsutism and acne). Found can prescribe and manage all of these; Hers cannot.
Pricing
| Component | Hers | Found |
|---|---|---|
| Monthly fee | ~$199/month | ~$99/month |
| Medication included | Yes (semaglutide) | Varies by medication |
| GLP-1 total (compounded) | $199/month all-in | ~$199–249/month (base + medication) |
| Non-GLP-1 medications | Not standard | Often lower total cost |
For GLP-1 specifically, Hers' $199/month all-in pricing competes with Found's ~$199–249/month total for GLP-1. For non-GLP-1 medications, Found's total cost can be substantially lower.
Coaching and Program
| Feature | Hers | Found |
|---|---|---|
| Dedicated health coach | No | Yes |
| Provider check-ins | Async | Regular |
| Behavioral support | Basic | Moderate |
| PCOS-specific guidance | Limited | Better (can address metabolic + hormonal) |
| Mental health integration | Hers platform offers mental health | Limited to behavioral weight coaching |
| Birth control coordination | Yes — Hers prescribes contraceptives | No |
The integrated women's health advantage (Hers): If you need both GLP-1 and birth control management, Hers can handle both within one platform. This is relevant given GLP-1 medications can interact with oral contraceptive absorption — having the same provider manage both has practical value.
Women-Specific Considerations
| Consideration | Hers | Found |
|---|---|---|
| PCOS management | Limited — GLP-1 only | Better — multi-medication approach |
| Menopause/perimenopause context | Better — hormone-aware platform | Limited |
| Birth control integration | Yes — same platform | No |
| Fertility considerations | Limited | Limited |
| Hormonal acne/hirsutism | Not directly addressed | Spironolactone available |
| OCP absorption interaction management | Better — same provider | No |
Head-to-Head: Who Should Choose Which
Choose Hers if:
- You want GLP-1 in a women's-focused brand experience
- You already use Hers for other health services (birth control, mental health, skin)
- You want one platform managing multiple women's health needs
- Semaglutide is your definite medication choice
- GLP-1 and oral contraceptive management from one provider is a priority
Choose Found if:
- You have PCOS or hormonal conditions benefiting from metformin or spironolactone alongside GLP-1
- You've had GLP-1 side effects and want non-GLP-1 alternatives
- A dedicated health coach is important to your program
- You want medication flexibility if GLP-1 isn't right for you
- Lower non-GLP-1 medication cost matters
Alternatives to Consider
| Provider | Why Consider | Monthly Cost |
|---|---|---|
| Calibrate | Insurance navigation + year-long program with behavioral health | ~$249 + medication |
| FORM Health | Deepest specialist care; strong for complex cases | $149+ |
| Noom Med | CBT behavioral curriculum | $149/month |
| Henry Meds | Fastest start; lowest long-term cash-pay | $149 → $129 |
Related Resources
- Best GLP-1 for Women — women-focused GLP-1 programs ranked
- GLP-1 for PCOS FAQ — GLP-1 and polycystic ovary syndrome
- GLP-1 Birth Control FAQ — contraception during GLP-1 treatment
- Hims vs Found — the men's equivalent comparison
- Found vs Henry Meds — Found vs another mid-tier platform
Related Guides
Best GLP-1 Options After Foundayo Approval: Oral vs Injectable 2026
Read guide →Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care
The best telehealth providers for tirzepatide in 2026, ranked by price, protocol, and care quality. From $278/month compounded to brand Zepbound via insurance. No provider paid for placement.
Read guide →Is Compounded Semaglutide Legal and Safe in 2026?
Is compounded semaglutide still legal? We break down the current FDA rules, 30 new warning letters, SAFE Drugs Act, Hims exiting compounded, and what this means for your prescription.
Read guide →Compounded Tirzepatide 2026: What's Happening and What Patients Should Do
Compounded tirzepatide is under active FDA enforcement as of March 2026 — supply is declining but not yet at zero. The 503B enforcement discretion ended over a year ago (March 2025); the FDA has now issued 50+ warning letters including a 30-letter batch in March 2026. Here's what patients need to know and what to do.
Read guide →